ImmuLogic starts over with FDA

ImmuLogic Pharmaceutical Corp. took two steps forward in its relations with the FDA, and two steps back in the timeline for development of its Allervax Cat peptide for cat allergy.

Based on its Dec. 19 meeting with the agency, the company last week said that it will begin a new study of Allervax Cat in the second quarter of 1997, to be followed by a larger study, prior to a PLA filing. The first trial

Read the full 744 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE